New laser vs. old laser: which is better for fixing nearsightedness?

NCT ID NCT07505264

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two laser platforms used in SMILE surgery to correct short-sightedness (myopia). The standard VISUMAX 500 will be tested against the newer VISUMAX 800 in 100 participants. Researchers want to see if the newer platform provides the same or better vision results and a more comfortable experience.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

SMILE surgery (laser procedure)

What this could lead to

If the newer VISUMAX 800 platform works as well or better, it could offer a faster or more comfortable option for laser eye surgery to correct short-sightedness.

What could go wrong

This is a small, early-stage comparison study with only 100 participants. The newer platform may not show meaningful improvement over the existing one, and individual results vary.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYOPIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myopia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Singapore National Eye Centre (SNEC)

    RECRUITING

    Singapore, 169856, Singapore

    Contact Phone: •••-•••-•••• Email: •••••@•••••